Frankfurt
21.07.26 | 08:07
0,524 Euro
-13,53 % -0,082
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 02.07. | AlzeCure Pharma: Final Outcome of AlzeCure's Rights Issue | 471 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 01.07. | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | 3 | Pharmaceutical Technology | ||
| 01.07. | Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal | 4 | FierceBiotech | ||
| 01.07. | AlzeCure Pharma Aktie schießt nach milliardenschwerem Lizenzdeal in die Höhe | 5 | Investing.com Deutsch | ||
| 01.07. | AlzeCure-Aktie: Milliarden-Deal treibt Kurs auf Hoch seit 2022 | 1 | Investing.com Deutsch | ||
| 01.07. | AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project | 479 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 1, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's... ► Artikel lesen | |
| 29.06. | Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026 | 614 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 29, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 29 June 2026, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's | 489 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: The subscription period in AlzeCure Pharma's Rights Issue begins today | 375 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE PUBLISHED, RELEASED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 15.06. | Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB | 213 | GlobeNewswire | With effect from June 16, 2026, the subscription rights in AlzeCure Pharma AB will be traded on First North Growth Market. Trading will continue up until and including June 25, 2026.
... ► Artikel lesen | |
| 10.06. | Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement | 6 | Pharmaceutical Technology | ||
| 10.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 10.06.2026 | 281 | Xetra Newsboard | Das Instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.06.2026 und ex Kapitalmassnahme am 11.06.2026 The instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY... ► Artikel lesen | |
| 09.06. | Lilly moves deeper into Alzheimer's research with AlzeCure licensing deal | 8 | FierceBiotech | ||
| 09.06. | Lilly, AlzeCure ink Alzheimer's drug deal worth more than $1B | 11 | Seeking Alpha | ||
| 09.06. | 1-Milliarde-Deal: Alzheimer-Hammer: Lilly schickt Mini-Biotech um 553 % nach oben | 886 | wallstreetONLINE | © Foto: OpenAIEli Lilly setzt mit AlzeCure auf eine Alzheimer-Tablette - und lässt die Aktie des kleinen Biotechs um mehr als 550 Prozent explodieren.Eli Lilly hat mit AlzeCure Pharma einen Kooperations-... ► Artikel lesen | |
| 09.06. | AlzeCure-Aktie explodiert um 301 % nach Alzheimer-Deal mit Eli Lilly | 19 | Investing.com Deutsch | ||
| 09.06. | AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer's Project | 846 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 9, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's... ► Artikel lesen | |
| 05.06. | AlzeCure Pharma AB: AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document | 423 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), which develops small molecule drug candidates for CNS disorders, with a focus on Alzheimer's disease and pain, has today resolved to proceed with the rights... ► Artikel lesen | |
| 26.05. | Notice To Annual General Meeting in AlzeCure Pharma AB | 524 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the... ► Artikel lesen | |
| 19.05. | AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain | 424 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 421,30 | +0,08 % | Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching | ||
| VIATRIS | 15,406 | +3,42 % | Mylan exits Biocon with Rs 3,679 crore block deal; ICICI Prudential MF emerges largest buyer | ||
| SELLAS LIFE SCIENCES | 11,350 | +3,65 % | Sellas Life (SLS) Climbs 12% Ahead of 'Potentially Company-Defining' Clinical Trial Result | ||
| ALTIMMUNE | 2,470 | +0,41 % | Altimmune, Inc: Altimmune Announces First Quarter 2026 Financial Results and Business Update | Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m.... ► Artikel lesen | |
| OPKO HEALTH | 1,060 | +0,95 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| JAGUAR HEALTH | 1,260 | 0,00 % | Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review | Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH
17.07.2026 / 17:49 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,555 | 0,00 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,560 | -1,54 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual... ► Artikel lesen | |
| LIPOCINE | 2,210 | +2,79 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 4,610 | -5,61 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces ... | - Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for... ► Artikel lesen | |
| PHOTOCURE | 5,140 | +0,39 % | Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics | OSLO, Norway, June 4, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics, today announced the signing and successful completion... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 20,800 | +1,96 % | Eurobio Scientific finalizes the acquisition of CareDX's transplant Lab Product division | EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio's strategic plan to become an in-vitro molecular diagnostics ("IVD") leaderCreation... ► Artikel lesen | |
| MEDICURE | 0,650 | +3,17 % | Medicure, Inc.: Medicure Announces CFO Change | WINNIPEG, MB / ACCESS Newswire / July 3, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| MERCK KGAA | 134,25 | -0,70 % | Merck investiert in neues Prüfzentrum für Europa | DARMSTADT (dpa-AFX) - Der Pharma- und Technologiekonzern Merck KGaA hat an seinem Hauptsitz Darmstadt ein neues Prüfzentrum für die Freigabe von Arzneimitteln eröffnet. Die Investition beziffert das... ► Artikel lesen | |
| BAYER | 47,620 | +0,32 % | Heftige Ausschläge im LifeScience-Sektor! Bayer, Vidac Pharma, BioNTech, Moderna und Evotec im Brennpunkt | Hier geht's rund! Aktuell erlebt die Krebsforschung durch die Verschmelzung von Zellanalyse und digitaler Präzision eine historische Zeitenwende. Mit einem neuen Management versucht BioNTech seine revolutionäre... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,524 Euro und damit -13,53 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.